Compare Cassava Sciences Inc (FLNA) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Otis Worldwide Corp — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Otis Worldwide Corp trades at $66.29 (market cap $25.17B). The key difference: Otis Worldwide Corp is far larger — about 638.8× Cassava Sciences Inc's market cap, and Otis Worldwide Corp pays a 2.66% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Otis Worldwide Corp for 65 Days on average.
| FLNA | OTIS | |
|---|---|---|
Market Cap | $39.40M | $25.17B |
Volume | 759,018 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $4.64 | $93.62 |
52-Week Low | $0.68 | $64.05 |
Typical Hold Time | 37 Days | 65 Days |
Enterprise Value | -$43.28M | $33.20B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Otis Worldwide trades at $65.74, down 1.07% on the day and near its 52-week low, reflecting bearish technical signals and recent earnings misses. The company maintains stable revenue around $14.4B USD with a net income margin of 10.17%, but faces margin pressure and a high debt-to-asset ratio of 75.54%. Recent news highlights CEO succession plans and mixed sentiment amid weak equipment demand in China.
The outlook is cautious with moderate upside to the $87.00 consensus price target, supported by a dominant service segment and institutional accumulation. Key risks include persistent margin compression, China exposure, and elevated leverage, requiring monitoring of service margin recovery for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
